ClinicalTrials.gg
Not yet recruitingNCT07857343Updated Oct 5, 2026

CardioFlow Transcatheter Mitral Valve Replacement System Pre-market Clinical Investigation

An interventional study of Microport CardioFlow Mitral Valve Replacement System in Degenerative Mitral Regurgitation, sponsored by Shanghai MicroPort CardioFlow Medtech Co., Ltd.. Not yet recruiting at 3 sites in China. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Shanghai MicroPort CardioFlow Medtech Co., Ltd. (part of MicroPort Scientific Corporation) · Not applicable, Interventional, and Treatment

How we know

Updated Oct 5, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
152
Allocation
Not applicable
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 57 studies in Mitral Valve Insufficiency with a site in China — 44 open to participants now, 46 under way, none of them phase 3. Mitral Valve Insufficiency · China.

Planned enrollment
13th of 40
152 · median 127
Started
2026
with 7 others
No phase
36 of 57
29 open now
Primary completion
2030-01
later than 40 of 45 live
Registered
54th of 57
by date

Among the 57 studies in Mitral Valve Insufficiency with a site in China, this one is the 13th largest by planned enrollment of the 40 interventional ones that give a count, is one of 8 that started in 2026, is one of 36 with no phase, reaches primary completion later than 40 of the 45 other live ones, and was the 54th registered.

Mitral Valve Insufficiency

471 studies on the registry are indexed under Mitral Valve Insufficiency; 165 are open to participants now.

Browse Mitral Valve Insufficiency studies →

Open to participants now

44 of the 57 studies in Mitral Valve Insufficiency with a site in China are open now. Recruiting first, the newest first:

39 more — sign in →

All 44 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 121 Mitral Valve Insufficiency studies recruiting now, 100 (83%) set no upper age limit and 6 (5%) stop at 75 or younger; 12 take children under 18; 1 takes healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies in Mitral Valve Insufficiency with a site in China, or all of them as a file.
02

Study summary

This is a prospective, multi-center, single-arm study to assess the safety and effectiveness of Microport CardioFlow Transcatheter Mitral Valve Replacement system in the treatment of moderate to severe or severe degenerative mitral regurgitation and to provide the clinical evidence for product registration in China or other countries

03

Conditions studied

  • Degenerative Mitral Regurgitation
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Subjects must meet all of the following criteria to be included in the study:

  • Subject has symptomatic, moderate-to-severe or severe, degenerative mitral regurgitation(MR≥3+);
  • functional class≥ II;
  • Heart team agrees that patient is unsuitable for treatment with conventional mitral valve surgery or transcatheter mitral valve edge-to-edge repair;
  • Subjects age ≥65 years old;
  • Subjects willing to sign for participation in the study and return for all required post-procedure follow-up visits;
  • Subjects anatomically suitable for the transcatheter mitral valve implantation

Subjects will be excluded from the study if any of the following conditions are present:

  • (LVEF)\<30%;
  • Left ventricular end diastolic diameter (LVEDD)>7.5cm;
  • Cardiac echography evidence of intracardiac mass, thrombus, or vegetation;
  • Severe tricuspid regurgitation with severe right ventricular dysfunction or any tricuspid valve disease requiring surgery or transcatheter intervention;
  • Aortic valve diseases requiring surgery or transcatheter intervention;
  • Any prohibitive mitral annular calcification(annulus to the leaflet) interferes the expansion of the device;
  • Prior surgical treatment of mitral valve;
  • Therapeutic cardiac surgical or interventional procedure within 30 days prior to the index procedure;
  • End-stage heart failure requiring left ventricular assist device or cardiac transplantation
  • Subjects with severe major vascular disease requiring surgical intervention or with aortic dissection
  • Need for emergent surgery
  • Hypertrophic or restrictive cardiomyopathy, constrictive pericarditis
  • Mitral valve pathological anatomy,LVOT anatomy, left atrial or ventricle anatomy not applicable for the device implantation;
  • Concurrent medical condition with a of less than 12 months
  • Evidence of an acute myocardial infarction or untreated coronary artery disease requiring revascularization within 30 days of enrollment.
  • Recent cerebrovascular events(ischemic or hemorrhage stroke, not including ) within 3 months of enrollment
  • Severe carotid stenosis( > 70%, both sides of carotid artery)
  • Any of the following: leukopenia, acute anemia, thrombocytopenia, history of bleeding diathesis, or coagulopathy if cannot be adequately treated;
  • Active endocarditis or active other infection
  • Active peptic ulcer or history of upper gastrointestinal bleeding within 3 months
  • Subject refuses the blood transfusion;
  • Known or to nitinol (titanium or nickel),bovine product, PET(Polyethylene terephthalate), contrast media; Inability to tolerate anti- or anticoagulants therapy; Contraindicated for transesophageal echocardiography (TEE)
  • Condition that prevents transapical access, such as chest malformation, ventricular aneurysm, apical thinning
  • Subjects with rheumatic mitral stenosis
  • Acute exacerbation of
  • Per heart team assessment, conditions that not suitable for transcatheter mitral valve replacement
  • Severe disabling Alzheimer's disease
  • Currently participating in an investigational drug or another device study that has not yet reached its primary endpoint
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
152 participants (estimated)

Study arms

  • Experimental
    MicroPort CardioFlow Transcatheter Mitral Valve Replacement

    Subjects with moderate to severe or severe degenerative mitral regurgitation will undergo transcatheter mitral valve replacement

    Device: Microport CardioFlow Mitral Valve Replacement System

Interventions

  • DeviceMicroport CardioFlow Mitral Valve Replacement System

    Patients will undergo transcatheter mitral valve replacement using Microport CardioFlow Mitral Valve Replacement System. The device is delivered via a transapical approach under the guidance of medical imaging equipment; the valve product loaded within the delivery system is advanced to the mitral annulus and released, thereby replacing the native mitral valve with pathological changes in function or anatomy.

06

What researchers measure

Primary outcomes

  1. Rate of cumulative all-cause mortality at 12 months post-procedure

    Time frame: 12 months

Secondary outcomes

  1. Rate of cumulative all-cause mortality at 30 days, 6 months and 2-5 years post procedure

    Time frame: 30 days, 6 months and 2-5 years post procedure

  2. Rate of heart failure rehospitalization at 30 days, 6 months and 2-5 years post procedure

    Time frame: 30 days, 6 months and 2-5 years post procedure

  3. Rate of disabling and non-disabling stroke at 30 days, 6 months, 12 months and 2-5 years post procedure

    Time frame: 30 days, 6 months, 12 months and 2-5 years post procedure

  4. Rate of myocardial infarction at 30 days, 6 months, 12 months and 2-5 years post procedure

    Time frame: 30 days, 6 months, 12 months and 2-5 years post procedure

  5. Rate of major assess site and vascular complications at 30 days, 6 months and 2-5 years post procedure

    Time frame: 30 days, 6 months and 2-5 years post procedure

  6. Rate of major and above bleeding defined by MVARC at 30 days, 6 months, 12 months and 2-5 years post procedure

    Time frame: 30 days, 6 months, 12 months and 2-5 years post procedure

  7. Rate of acute kidney injury (stage 2/3) at 30 days, 6 months, 12 months and 2-5 years post procedure

    Time frame: 30 days, 6 months, 12 months and 2-5 years post procedure

  8. Rate of arrhythmias and conduction system disturbances at 30 days, 6 months, 12 months and 2-5 years post procedure

    Time frame: 30 days, 6 months, 12 months and 2-5 years post procedure

  9. Rate of permanent pacemaker implantation at 30 days, 6 months, 12 months and 2-5 years post procedure

    Time frame: 30 days, 6 months, 12 months and 2-5 years post procedure

  10. Rate of mitral valve reoperation at 30 days, 6 months and 2-5 years post procedure

    Time frame: 30 days, 6 months and 2-5 years post procedure

  11. Technical success rate defined by MVARC at immediate post procedure

    Time frame: immediate post procedure

  12. Device success rate defined by MVARC at 30 days post procedure

    Time frame: 30 days post procedure

  13. Procedural success rate defined by MVARC at 30 days

    Time frame: 30 days

  14. Bioprosthesis haemodynamic function

    Mitral regurgitation (paravalvular leak and intra-valvular regurgitation)

    Time frame: 30 days, 6 months, 12 months and 2-5 years

  15. Bioprosthesis haemodynamic function

    Mitral valve area

    Time frame: 30 days, 6 months, 12 months and 2-5 years

  16. Bioprosthesis haemodynamic function

    Mitral valve transvalvular pressure gradient

    Time frame: 30 days, 6 months, 12 months and 2-5 years

  17. Change in NYHA classification at 30 days, 6 months, 12 months and 2-5 years post procedure

    Time frame: 30 days, 6 months, 12 months and 2-5 years post procedure

  18. Change in QoL score from baseline at 30 days, 6 months, 12 months and 2-5 years as assessed by KCCQ

    Time frame: 30 days, 6 months, 12 months and 2-5 years

  19. Change in 6 minute walk test at 30 days, 6 months, 12 months and 2-5 years

    Time frame: 30 days, 6 months, 12 months and 2-5 years

  20. Rate of device-related technical failure issues and complications defined by MVARC at 30 days, 6 months, 12 months and 2-5 years post procedure

    Time frame: 30 days, 6 months, 12 months and 2-5 years post procedure

07

Study locations

3 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Jan 2030, 37 months later.

Of 91 industry-sponsored interventional studies with no phase under Mitral Valve Insufficiency, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 144. This study's planned 37 months is below that.

Counting every sponsor, half of 144 studies reached it within 56 months; a quarter within 25 and three quarters within 108.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2026
First posted
Oct 5, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Jan 1, 2030
CompletionEst.
Jan 1, 2035
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07857343
Responsible party
Sponsor
First posted
Oct 5, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Jan 1, 2030 (estimated)
Completion
Jan 1, 2035 (estimated)
Last update
Oct 5, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion